ArticleOpen veterinary journal2026
Different dose-based multi HN&F epitope mRNA vaccine against Newcastle disease.
Article in Open veterinary journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Newcastle disease virus (NDV) is considered a major player in the ongoing challenges in the poultry farming system due to its virulence, which affects productivity. Aim: This study aimed to develop and evaluate a multi-epitope mRNA vaccine that targets the NDV fusion (F) and hemagglutinin-neuraminidase (HN) proteins in chickens. Methods: The cytotoxic T lymphocyte (CTL) epitopes were obtained from NetCTL 1.2, whereas the helper T lymphocyte (HTL) epitopes were predicted using the IEDB MHC-II binding prediction tool. The subsequent selection of the epitopes was via binding affinity and was also predicted antigenically (VaxiJen v2.0) and allergenically (AllerTOP v2.0), and for sequence conservancy. The selected epitopes were fused with Alanine-Alanine-Tyrosine, Glycine-Proline-Glycine-Proline-Glycine, and Lysine-Lysine linkers. The vector was constructed, and the sequence was validated using VectorBee. There were 280 chickens distributed randomly across eight sets ( Results: Several epitopes for CTL, HTL, and B-cells that were both conservatively positioned and highly immunogenic were identified for the F and HN proteins. In the experiment, chickens that were immunized with the multi-epitope mRNA vaccine had significantly higher HI antibody titers and ELISA optical density values than the negative control group. The mRNA vaccine group had statistically significant differences in lymphocyte proliferation and the number of IFN-γ-producing cells. After the virulent NDV challenge, the mRNA vaccine group had the best protection with the fewest and least severe clinical signs and the lowest mortality. Conclusion: The mRNA vaccine for the F and HN multi-epitopes NDV was the first to provide extensive protection against NDV. The vaccine elicited strong immune responses, demonstrating the potential of mRNA multi-epitope-based vaccines for NDV as a significant improvement over the previous method.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.